Immunovant, Inc.
IMVT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001764013
In the last 90 days, Immunovant, Inc. insiders filed 0 open-market purchases and 10 sales; 226 institutions reported holding it in 13F filings for Q2 2026, worth $4.25B in total; Greenlight Capital is the only superinvestor holding it.
Q1 2023 vs. Q4 2022
How the institutions holding Immunovant, Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 133 | 142 | +9 |
| Shares | 56.5M | 58.3M | +1.74M (+3.1%) |
| Value | $1.00B | $903.7M | −$99.6M (−9.9%) |
New holders (25)
Institutions that held Immunovant, Inc. at the end of Q1 2023 but not at the end of Q4 2022.
Sold out (16)
Institutions that held Immunovant, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Walleye Capital LLC | 533,840 | $9.48M |
| Silverarc Capital Management, LLC | 519,614 | $9.22M |
| Point72 Asset Management, L.P. | 435,751 | $7.73M |
| Cormorant Asset Management, LP | 400,000 | $7.10M |
| Balyasny Asset Management LLC | 375,775 | $6.67M |
| Norges Bank | 211,600 | $3.76M |
| HSBC Holdings PLC | 49,592 | $862.4K |
| The PNC Financial Services Group, Inc. | 45,601 | $809.4K |
| Jupiter Asset Management Ltd | 42,082 | $745.3K |
| Marshall Wace, LLP | 38,953 | $691.4K |
| Kula Investments, LLC | 29,562 | $524.7K |
| Walleye Trading LLC | 28,051 | $497.9K |
| Concorde Asset Management, LLC | 16,725 | $296.9K |
| Quantamental Technologies LLC | 12,301 | $218.3K |
| Denali Advisors LLC | 3,900 | $69.2K |
| Rockefeller Capital Management L.P. | 224 | $3.00K |